NCT00554658

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of Regensburg · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. Main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Quetiapine	Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-12-01
• Completion: 2011-03-01
• First posted: 2007-11-07
• Last updated: 2011-10-24

Locations

1 site across 1 country: Germany